Government-Owned Inventions; Availability for Licensing and Cooperative Research and Development Agreements (CRADAs), 11671 [E6-3267]
Download as PDF
<![CDATA[
Federal Register / Vol. 71, No. 45 / Wednesday, March 8, 2006 / Notices
Dated: March 2, 2006.
Alvin Hall,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. E6–3261 Filed 3–7–06; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Government-Owned Inventions;
Availability for Licensing and
Cooperative Research and
Development Agreements (CRADAs)
AGENCY: Centers for Disease Control and
Prevention Technology Transfer Office;
Department of Health and Human
Services.
ACTION:
Notice.
SUMMARY: The invention named in this
notice is owned by agencies of the
United States Government and is
available for licensing in the United
States (U.S.) in accordance with 35
U.S.C. 207, and is available for
cooperative research and development
agreements (CRADAs) in accordance
with 15 U.S.C. 3710a, to achieve
expeditious commercialization of
results of federally funded research and
development. A provisional patent
application has been filed. A Patent
Cooperation Treaty (PCT) application
and national stage foreign patent
applications claiming priority to the
Patent Cooperation Treaty (PCT)
application are expected to be filed
within the appropriate deadlines to
extend market coverage for U.S.
companies and may also be available for
licensing.
Licensing and CRADA
information, and information related to
the technology listed below, may be
obtained by writing to Suzanne Seavello
Shope, J.D., Technology Licensing and
Marketing Scientist, Technology
Transfer Office, Centers for Disease
Control and Prevention (CDC), Mailstop
K–79, 4770 Buford Highway, Atlanta,
GA 30341, telephone (770)488–8613;
facsimile (770)488–8615; or e-mail
sshope@cdc.gov. A signed Confidential
Disclosure Agreement (available under
Forms at https://www.cdc.gov/tto) will be
required to receive copies of
unpublished patent applications and
other information.
erjones on PROD1PC68 with NOTICES
ADDRESSES:
VerDate Aug<31>2005
15:53 Mar 07, 2006
Jkt 208001
Diagnostics
Immunoassay for Diagnosis of
Orthopoxvirus Infection
A CDC-developed immunoassay may
be used for the diagnosis of infection
with Orthopoxviruses (e.g. Monkeypox,
Variola) by detection of acute phase
immune responses that correlate to
recent infection. With recent recognition
of Orthopox viruses as emerging
infectious agents with zoonotic
transmission capabilities as well as
select agents for bioterrorism, assays for
the detection or diagnosis of infections
are sought. This assay provides a rapid
and simple method for detection of
infection with these viruses related to
zoonotic transmission or bioterrorism
events involving such viruses.
Use of the assay produced high levels
of sensitivity during the 2003
Monkeypox outbreak in North America
when compared to PCR.
Commercialization of the ELISA test
may provide a standard screening tool
for diagnosis of Orthopoxvirus as well
as a surveillance tool for exposure.
The immunoassay may also be useful
at the state level for BT surveillance
including an opportunity for use in
reference labs. Reagents used in the
assay are available through CDC
laboratories and for commercial
development of the assay. Further
refinement of the assay may result in the
development of additional reagents for
incorporation into the assay.
Inventors: Kevin L. Karem, Inger K.
Damon and Joanne L. Patton.
CDC Ref. #: I–014–04.
James D. Seligman,
Chief Information Officer, Centers for Disease
Control and Prevention.
[FR Doc. E6–3267 Filed 3–7–06; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Government-Owned Inventions;
Availability for Licensing and
Cooperative Research and
Development Agreements (CRADAs)
AGENCY: Centers for Disease Control and
Prevention, Technology Transfer Office,
Department of Health and Human
Services.
ACTION: Notice.
SUMMARY: The invention named in this
notice is owned by agencies of the
United States Government and is
available for licensing in the United
PO 00000
Frm 00099
Fmt 4703
Sfmt 4703
11671
States (U.S.) in accordance with 35
U.S.C. 207, and is available for
cooperative research and development
agreements (CRADAs) in accordance
with 15 U.S.C. 3710a, to achieve
expeditious commercialization of
results of federally funded research and
development. A provisional patent
application has been filed. In addition,
the invention is protected by copyright
registration. A Patent Cooperation
Treaty (PCT) application and national
stage foreign patent applications
claiming priority to the Patent
Cooperation Treaty (PCT) application
are expected to be filed within the
appropriate deadlines to extend market
coverage for U.S. companies and may
also be available for licensing.
ADDRESSES: Licensing and CRADA
information, and information related to
the technology listed below, may be
obtained by writing to Suzanne Seavello
Shope, J.D., Technology Licensing and
Marketing Scientist, Technology
Transfer Office, Centers for Disease
Control and Prevention (CDC), Mailstop
K–79, 4770 Buford Highway, Atlanta,
GA 30341, telephone (770)488–8613;
facsimile (770)488–8615; or e-mail
sshope@cdc.gov. A signed Confidential
Disclosure Agreement (available under
Forms at www.cdc.gov/tto) will be
required to receive copies of
unpublished patent applications and
other information.
Software
Computer Software for Automating
Permeation Testing Data Analysis
Data analysis for chemical protective
clothing (CPC) permeation testing
involves a number of equations and
experimental factors. Experimenter bias
and possible calculation errors are
critical issues when determining
permeation parameters. In order to
compare results among different
laboratories and manufacturers, the
normalized breakthrough time is
required since it is not dependent on the
detection limits of the analytical system.
However, calculating the normalized
breakthrough time requires the use of
polynomial curve fitting, polynomial
derivatives, and quadratic equations.
Solving these equations, without a
computer program, would be very
difficult. Therefore, a unique computer
program using Microsoft Visual C++,
referred to as ‘‘Permeation Calculator’’,
has been developed at the National
Institute for Occupational Safety and
Health/National Personal Protective
Technology Laboratory (NIOSH/NPPTL)
to calculate the permeation parameters.
The program imports data and then
calculates the permeation parameters;
E:\FR\FM\08MRN1.SGM
08MRN1
]]>Agencies
[Federal Register Volume 71, Number 45 (Wednesday, March 8, 2006)]
[Notices]
[Page 11671]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-3267]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Government-Owned Inventions; Availability for Licensing and
Cooperative Research and Development Agreements (CRADAs)
AGENCY: Centers for Disease Control and Prevention Technology Transfer
Office; Department of Health and Human Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention named in this notice is owned by agencies of the
United States Government and is available for licensing in the United
States (U.S.) in accordance with 35 U.S.C. 207, and is available for
cooperative research and development agreements (CRADAs) in accordance
with 15 U.S.C. 3710a, to achieve expeditious commercialization of
results of federally funded research and development. A provisional
patent application has been filed. A Patent Cooperation Treaty (PCT)
application and national stage foreign patent applications claiming
priority to the Patent Cooperation Treaty (PCT) application are
expected to be filed within the appropriate deadlines to extend market
coverage for U.S. companies and may also be available for licensing.
ADDRESSES: Licensing and CRADA information, and information related to
the technology listed below, may be obtained by writing to Suzanne
Seavello Shope, J.D., Technology Licensing and Marketing Scientist,
Technology Transfer Office, Centers for Disease Control and Prevention
(CDC), Mailstop K-79, 4770 Buford Highway, Atlanta, GA 30341, telephone
(770)488-8613; facsimile (770)488-8615; or e-mail sshope@cdc.gov. A
signed Confidential Disclosure Agreement (available under Forms at
https://www.cdc.gov/tto) will be required to receive copies of
unpublished patent applications and other information.
Diagnostics
Immunoassay for Diagnosis of Orthopoxvirus Infection
A CDC-developed immunoassay may be used for the diagnosis of
infection with Orthopoxviruses (e.g. Monkeypox, Variola) by detection
of acute phase immune responses that correlate to recent infection.
With recent recognition of Orthopox viruses as emerging infectious
agents with zoonotic transmission capabilities as well as select agents
for bioterrorism, assays for the detection or diagnosis of infections
are sought. This assay provides a rapid and simple method for detection
of infection with these viruses related to zoonotic transmission or
bioterrorism events involving such viruses.
Use of the assay produced high levels of sensitivity during the
2003 Monkeypox outbreak in North America when compared to PCR.
Commercialization of the ELISA test may provide a standard screening
tool for diagnosis of Orthopoxvirus as well as a surveillance tool for
exposure.
The immunoassay may also be useful at the state level for BT
surveillance including an opportunity for use in reference labs.
Reagents used in the assay are available through CDC laboratories and
for commercial development of the assay. Further refinement of the
assay may result in the development of additional reagents for
incorporation into the assay.
Inventors: Kevin L. Karem, Inger K. Damon and Joanne L. Patton.
CDC Ref. #: I-014-04.
James D. Seligman,
Chief Information Officer, Centers for Disease Control and Prevention.
[FR Doc. E6-3267 Filed 3-7-06; 8:45 am]
BILLING CODE 4163-18-P
